We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...
A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...
A new study co-written by a University of Illinois Urbana-Champaign expert in operations management finds that drugs approved ...
About Kinaset Therapeutics, Inc. Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. With founding investors 5AM ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...
The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...
Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its ...
The European Commission has approved Sanofi’s Teizeild as the first disease-modifying therapy in the EU to delay the onset of stage 3 type 1 diabetes in adults and children with stage 2 T1D. Supported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback